Sort
25,944 grants matching “neurodegeneration”
Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain
$499,863Christopher Dockendorff · Function Therapeutics, Inc. · R43 · FY2025 · NS
Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease
$499,860Michael R Ruff · Creative Bio-Peptides, Inc. · R43 · FY2021 · AG
Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
$499,754David Hastings Cribbs · Nuravax, Inc. · R44 · FY2025 · AG
Microbiome, Environment, and Parkinsons disease (MEP) PESTICIDE EXPOSURES AND THE GUT MICROBIOME IN PARKINSONS DISEASE
$499,701Beate R Ritz · University Of California Los Angeles · R01 · FY2024 · ES
BMAL1/ARNTL plays a critical, non-circadian role in secondary tissue damage after contusive SCI
$499,606Michal Hetman · University Of Louisville · R01 · FY2024 · NS
Evaluating microtubule binding as a potential imaging biomarker for Alzheimer's disease
$499,595Kiran Solingapuram Sai · Wake Forest University Health Sciences · R01 · FY2020 · AG
Serological profiling of the human virome and ALS risk in a military population
$499,585Alberto Ascherio · Harvard School Of Public Health · R01 · FY2022 · TS
Xenon gas treatment to modulate microglia in neurodegenerative diseases
$499,546Ilya Ilin · General Biophysics, Llc · R41 · FY2021 · AG
Optimizing virtual hits of human CGAS inhibitors to treat neurodegeneration
$499,540Anjana Sinha · Aeton Therapeutics, Inc. · R43 · FY2023 · AG
System for advanced automated 3D microvascular analysis in neuroplasticity
$499,533Paul Angstman · Microbrightfield, Llc · R44 · FY2016 · MH
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach
$499,533Susan A Gauthier · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · NS
Neuromodulation and Neurodegeneration: the Missing Link and Mechanisms of Action
$499,500Viviana Gradinaru · California Institute Of Technology · DP2 · FY2018 · NS
Drug Discovery Pipeline Targeting Pathologically Leaky Calcium Release Channels in Age-Related Indications
$499,443Jennifer Jewell Thomas · Photonic Pharma, Llc · R43 · FY2021 · AG
First-in-human study of MW151, a novel drug targeting neuroinflammation
$499,320Victor Shifrin · Immunochem Therapeutics, Llc · R44 · FY2018 · AG
Network Medicine for Alzheimers Disease: Functional Dissection and Pharmacologic Perturbation of a Human Brain Synaptic Regulatory Expression Signature
$499,303Joshua M Shulman · Baylor College Of Medicine · R01 · FY2025 · AG
Novel regulation of autophagic flux for the treatment of Alzheimer's disease
$499,272William J Greenlee · Ceracuity, Inc. · R43 · FY2022 · AG
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer Disease
$499,198William C Mobley · University Of California, San Diego · R01 · FY2018 · AG
Amyloid-β Disruption of Pericyte Control of Capillary Hemodynamics
$499,103Albert Louis Gonzales · University Of Nevada Reno · R01 · FY2025 · AG
Identifying signatures of brain aging through heterochronic blood exchange
$499,075Yi Zuo · University Of California Santa Cruz · R01 · FY2021 · AG
Experimental Creutzfeldt Jacob Disease
$499,024Laura Manuelidis · Yale University · R01 · FY2008 · NS
ROLE OF TFEB IN TAUOPATHY
$498,954Hui Zheng · Baylor College Of Medicine · R01 · FY2024 · NS
ROLE OF TFEB IN TAUOPATHY
$498,954Hui Zheng · Baylor College Of Medicine · R01 · FY2025 · NS
Replication mechanism of human prions
$498,859Jiri G. Safar · Case Western Reserve University · R01 · FY2015 · NS
Alzheimer's tauopathy phenotype and the microRNA22-3p: implication for pathogenesis
$498,758Domenico Pratico · Temple Univ Of The Commonwealth · R01 · FY2025 · AG
Elucidation of the mechanisms by which Ms4a genes regulate neurodegeneration in Alzheimerâs Disease and related disorders
$498,748Paul Lieberman Greer · Univ Of Massachusetts Med Sch Worcester · R56 · FY2024 · AG